GeNeuron Therapeutics

GeNeuron Therapeutics is a clinical-stage biotechnology company focused on developing transformative gene therapies for neurodegenerative disorders, particularly Amyotrophic Lateral Sclerosis (ALS). The company's lead candidate, GN-001, is an adeno-associated virus (AAV) vector-based therapy designed to deliver the Hepatocyte Growth Factor (HGF) gene directly to the central nervous system. This approach aims to provide neuroprotection, promote axonal regeneration, and modulate neuroinflammation to slow disease progression in patients with ALS. GeNeuron utilizes proprietary AAV technology and optimized promoters to enhance delivery efficiency and safety across its development programs. The company maintains a cross-border operational model with facilities in both the United States and China to leverage global expertise in neuroscience and clinical development.